IL-6 produced by macrophages infected with Mycobacterium species suppresses T cell responses

J Immunol. 1997 Jan 1;158(1):330-7.

Abstract

The ability of Mycobacterium bovis Calmette-Guérin bacillus-infected bone marrow-derived macrophages to process and present exogenously added Ags to T cells and stimulate their growth and production of IL-2 was examined. The infected macrophages were inhibited in their ability to activate T cells, and this inhibition could be transferred to uninfected macrophages with filtered supernatants from mycobacteria-infected macrophages. The inhibition was not due to decreases in macrophage viability, Ag uptake, or cell surface expression of MHC class II or other accessory molecules necessary for Ag presentation. Other intracellular pathogens such as Listeria monocytogenes and Leishmania mexicana did not induce the soluble inhibitory factor, while Mycobacterium avium strain 101 did, suggesting the factor is specific to infection with mycobacteria. The inhibitory effect was reversed completely by preincubation with neutralizing Abs against IL-6, and rIL-6 partially restored the effect. Approximately 10,000-fold more IL-6 was produced by mycobacteria-infected macrophages compared with uninfected controls. Such sustained levels of IL-6 may account for the immune unresponsiveness apparent in both human and murine mycobacterial disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Female
  • Immunosuppressive Agents / pharmacology*
  • Interleukin-6 / biosynthesis*
  • Interleukin-6 / pharmacology*
  • Leishmania mexicana / pathogenicity
  • Listeria monocytogenes / pathogenicity
  • Lymphocyte Activation / drug effects*
  • Macrophages / metabolism*
  • Macrophages / microbiology*
  • Mice
  • Mice, Inbred CBA
  • Mycobacterium avium / pathogenicity
  • Mycobacterium bovis / isolation & purification
  • Mycobacterium bovis / pathogenicity*
  • T-Lymphocytes / drug effects*

Substances

  • Immunosuppressive Agents
  • Interleukin-6